What is the Y-tunnus number of Aspen Pharma Ireland Limited, Suomen sivuliike?

Aspen Pharma Ireland Limited, Suomen sivuliike is registered with PRH / YTJ under Y-tunnus 2913568-9.

How many employees does Aspen Pharma Ireland Limited, Suomen sivuliike have?

Aspen Pharma Ireland Limited, Suomen sivuliike employs 20 people as of the latest annual report.

Nina Kjaervoll is Person with significant control of Aspen Pharma Ireland Limited, Suomen sivuliike, in role since 2023.

Aspen Pharma Ireland Limited, Suomen sivuliike's registered address is Fabianinkatu 29-B.

SLDissolved

Y-tunnus 2913568-9Fabianinkatu 29B, 00100 HelsinkiWholesale of pharmaceutical and medical goods · NACE 4646Est. 201820 employees

Actively employed in the business

Name	Role	Member since
Current (4)
NK Nina Kjaervoll Person with significant control	Person with significant control	2023
Cv Carnie van der Linde Foreign representative	Foreign representative	2026
KW Karolina Wita Szkudlarek Foreign representative	Foreign representative	2022
DV Daniel Vella Friggieri Foreign representative	Foreign representative	2023
Former (9)
NV Naudé Vanwyk De Klerk Foreign representative	Foreign representative	2018 – 2024
DD Dennis Dencher Foreign representative	Foreign representative	2018 – 2019
CM Chris Mynhard Botha Foreign representative	Foreign representative	2019 – 2026
PG Petra Gabriele Schaller Foreign representative	Foreign representative	2018 – 2020
MT Mads Tang Dalsgaard Person with significant control	Person with significant control	2018 – 2020
TK Thomas Kerscher Foreign representative	Foreign representative	2021 – 2023
TH Thorbjørn Hjarndal Person with significant control	Person with significant control	2020 – 2023
DD Derek Davies Foreign representative	Foreign representative	2018 – 2020
AF Alan Francis Quinn Foreign representative	Foreign representative	2018 – 2022

Non-executive oversight

No data on file.

As of last annual report

No shareholder data available.

Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.